Immunotherapy for Colorectal Cancer
AbstractThe recent success of anti-PD1 drugs in metastatic colorectal cancer patients with mismatch repair deficiency generated overwhelming enthusiasm for immunotherapy in the disease. However, patients with mismatch repair deficient colorectal cancer represent only a small subset of the metastatic population. Current research focuses on advancing immunotherapy to earlier stages of the disease including adjuvant and first-line metastatic settings, and on inducing sensitivity to immune checkpoint inhibitor therapy through a combinatorial approach. Here, we review the contemporary understanding of the immune and molecular landscape in colorectal cancer and discuss ongoing clinical trials evaluating novel combination regimens based on immune checkpoint inhibitors. View Full-Text
Share & Cite This Article
Boland, P.M.; Ma, W.W. Immunotherapy for Colorectal Cancer. Cancers 2017, 9, 50.
Boland PM, Ma WW. Immunotherapy for Colorectal Cancer. Cancers. 2017; 9(5):50.Chicago/Turabian Style
Boland, Patrick M.; Ma, Wen W. 2017. "Immunotherapy for Colorectal Cancer." Cancers 9, no. 5: 50.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.